{"name":"Renovo","slug":"renovo","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":43000,"revenueGrowth":0,"grossMargin":0,"rdSpend":6025000,"netIncome":-8814000,"cash":8118000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2024"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"oncology","drugs":[{"name":"Juvista","genericName":"Juvista","slug":"juvista","indication":"Other","status":"discontinued"},{"name":"Juvista (Avotermin)","genericName":"Juvista (Avotermin)","slug":"juvista-avotermin","indication":"Reduction of scar formation in acute surgical wounds","status":"phase_3"},{"name":"Juvidex","genericName":"Juvidex","slug":"juvidex","indication":"Other","status":"phase_2"},{"name":"Prevascar","genericName":"Prevascar","slug":"prevascar","indication":"Other","status":"phase_2"},{"name":"Zesteem","genericName":"Zesteem","slug":"zesteem","indication":"Other","status":"phase_2"},{"name":"estradiol (Zesteem)","genericName":"estradiol (Zesteem)","slug":"estradiol-zesteem","indication":"Treatment of menopausal symptoms, including hot flashes and vaginal dryness","status":"phase_3"}]}],"pipeline":[{"name":"Juvista","genericName":"Juvista","slug":"juvista","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Juvista (Avotermin)","genericName":"Juvista (Avotermin)","slug":"juvista-avotermin","phase":"phase_3","mechanism":"Avotermin is a recombinant human transforming growth factor beta-3 (TGF-β3) that modulates wound healing to reduce scarring.","indications":["Reduction of scar formation in acute surgical wounds","Improvement of cosmetic outcomes in wound healing"],"catalyst":""},{"name":"Juvidex","genericName":"Juvidex","slug":"juvidex","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Prevascar","genericName":"Prevascar","slug":"prevascar","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Zesteem","genericName":"Zesteem","slug":"zesteem","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"estradiol (Zesteem)","genericName":"estradiol (Zesteem)","slug":"estradiol-zesteem","phase":"phase_3","mechanism":"Estradiol acts as an estrogen receptor agonist, mimicking the effects of the naturally occurring hormone estrogen in the body.","indications":["Treatment of menopausal symptoms, including hot flashes and vaginal dryness","Prevention of osteoporosis in postmenopausal women"],"catalyst":""}],"recentEvents":[],"realNews":[{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-30","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOMzJaZDZ3SzFyRnh1d0JNYldIc3ZETUlZT0U3blRtaE42TFBUek4zQnhyVVFLYlkwX2JZT2dPVER2eURVZVBuWU1fM1V3QjgtSUtpanduTWVhSlBIOVJuN2x4bFhfakxoaktmNzFIMnVrelBYTS1fVG9oSGM0eURub0N5bk51MHNEamduY1VtbmRoTnRNb2N0eE5xbUw2NHdXNTY2OQ?oc=5","date":"2025-09-18","type":"pipeline","source":"globalventuring.com","summary":"Nakada retires from investor role at pharma group Johnson & Johnson - globalventuring.com","headline":"Nakada retires from investor role at pharma group Johnson & Johnson","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPV0ZFTzdDVmR5bXREYXRnUEJTbUc3UmZRLS02N1ptSVdkRHFUZ2ZwVFl2MTZXanpKa0hodWRnVkVhQnlSa2NTOWlmMDdCMWIwNXoxZURfYlhWSUl6Ynk4QlZVdVpZMjRVVE1KSDJoZjJhLXl6VHl2WEMyVFZLVXUyNngxR3V3Q2JhWGc?oc=5","date":"2022-08-22","type":"pipeline","source":"Pharmacy Times","summary":"Expert Discusses Drug Diversion in the Pharmacy - Pharmacy Times","headline":"Expert Discusses Drug Diversion in the Pharmacy","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2021-05-07","type":"pipeline","source":"Medical Dialogues","summary":"JB Chemicals & Pharmaceuticals Ltd (JBCPL) enters the Nephrology segment in India, launches Renova... - Medical Dialogues","headline":"JB Chemicals & Pharmaceuticals Ltd (JBCPL) enters the Nephrology segment in India, launches Renova...","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPWko0OVdiV2VrajJ2TGpZNmRLVkRDazgzb1VacGdQeWdPNHhqYzFPakZSWDhiREk2Q2I0aHE2MTRsRElmWmhidmozb1J4cGNVMFZhWEJGdWJNZ3I5cWtiZVJITG1makJBWE9NVmJTeDFkaDB1UGsya2pnTkZibVRoU3JZRERic2N1VFNUOFlyVHBodndwSGt2SVI3dWl4Z21ibzZGYmxiR2p6UVlTNmc?oc=5","date":"2017-09-28","type":"pipeline","source":"pharmatimes.com","summary":"NeRRe Therapeutics appoints Andrew Kay as chairman of the Board - pharmatimes.com","headline":"NeRRe Therapeutics appoints Andrew Kay as chairman of the Board","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPbEVWQVVReUxmRjdBYTZ6XzFIYzJDbzVzaEM3dkJGV21nQ1NZN0ZTLWZ3akdLd3p5WG8tOExOM3ZrTUtVX0VTZERvaFFldU1CUVdhSGF1Uy12Mk5JZkRmWk84Y0NqdzNDT1ZPelpZRnhLMXJ3c1cxUWM1N2NUY3ByYjlLdzlOV0ZmNGlieVNaSGFweVp3Mm5xLXdxNGxDeWNnQlo5UnVDT2RvUWxQVWFrN09R?oc=5","date":"2016-12-14","type":"regulatory","source":"Fierce Pharma","summary":"Transdermal patch maker gets FDA warning letter for subpotent product - Fierce Pharma","headline":"Transdermal patch maker gets FDA warning letter for subpotent product","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQR2k5N0xoN0hNZVpTZ1pEMUZycktpTU5NMHkxYmF3YjNOcDBSREQ5WkZ2WjZWeDFlc25IMS1pdGhCZDI0OFJDc01TY0lJYnJCRGdPNEFRTVk1N1JlV09JWVdHUDJZUWsxdjNQbjM2a0xMOUxzUFVsR1FjZWxmNXMxVFRBemtoWUF4dm1fcS1SYW9YRzZVdFF2eUFQMTVCUzhzV0E?oc=5","date":"2012-04-16","type":"pipeline","source":"proactiveinvestors.com","summary":"Renovo ends Prevascar development - proactiveinvestors.com","headline":"Renovo ends Prevascar development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxQcjBidXQ2SE43V0EzOGFyUmxzM1hrX3Y5bHI3Q2ZJN0w0OGcydWxTb2dCWl9TRnFqZ1ltTWRKa2pMSjR0dFZNaTZZZkxMS3FfMkxGc0o4TWZSRTJZTFZ2dmYwRFVkd21kTDFiNjZ6enBmNURLUWJkNUpfblhBOHA3YlV1cHN0NTBUN1B3Yko2X0lzTV80MDk5ZllDN1ZiRVFlVFFxTUk0ZVdiTmpYdElYVXlQTUFfVGlUckJVenFnSUhYWEllTm9xVTgzN0lnLVNseWdMc0NmS0tMNEVPUm9pVGtB?oc=5","date":"2010-02-10","type":"pipeline","source":"proactiveinvestors.com","summary":"Renovo still appropriately funded for ongoing investment in development portfolio - proactiveinvestors.com","headline":"Renovo still appropriately funded for ongoing investment in development portfolio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE9qUU9zSlhiYXFLMzNlbHRVYnEtY2dlTW4tcnRmYnhXU1dGWUJDTEFMclhlcmFVQVlIRnl5N3RuUUl6bkRURUNlOEIwLS1SYk9KTENaTDE2VVk1RkRUR196VEctSV83ZWttZzVhUTkzLWdxX196X1FhVVlGSjI?oc=5","date":"2006-10-25","type":"pipeline","source":"Pharmaceutical Technology","summary":"Core Technology Facility, University Of Manchester, Manchester - Pharmaceutical Technology","headline":"Core Technology Facility, University Of Manchester, Manchester","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"discontinued":1,"phase_3":2,"phase_2":3},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":43000,"revenuePeriod":"2024-12-31","revenueHistory":[{"value":43000,"period":"2024-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":6025000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-8814000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":8118000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}